🇺🇸 FDA
Pipeline program

225Ac-LNC1011

FirstAHFujian-225Ac-LNC1011

Phase 2 small_molecule active

Quick answer

225Ac-LNC1011 for Prostate Cancer is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials